OncoDNA Signs Agreement With SOLTI To Provide Tumor Molecular Profile Analysis To Breast Cancer Patients In AGATA Screening Program

BRUSSELS & BARCELONA, Spain--(BUSINESS WIRE)--Belgium-based OncoDNA SA, The Cancer Theranostic Company, which supplies the only comprehensive solution from cancer profiling (OncoDEEP&TRACE), combining solid and liquid biopsies analysis to help oncologists with drug treatment options and efficacy monitoring, has signed a partnership agreement, through its Spanish distributor BioSequence, with SOLTI, a non-profit organization dedicated to clinical research in breast cancer with a broad network of leading hospital centers in Spain, Portugal, France and Italy to supply tumor molecular profiling analysis for SOLTI’s AGATA breast cancer screening program.

AGATA, the pilot trial of a genomic screening program pioneered in Spain, aims to refer breast cancer patients to clinical trials based on their molecular profile. With this partnership, SOLTI takes advantage of OncoDNA’s solid experience in data processing to streamline and customize patient data collection.

“This collaboration is a great opportunity to exchange knowledge and know-how between OncoDNA and SOLTI, both organizations focused on improving cancer patient care. We are excited to work together to enhance the outcomes we provide through the AGATA program to better direct patients to clinical trials according to their tumor profile,” said Dr. Eva Ciruelos, President of SOLTI.

As part of the agreement, OncoDNA will customize its OncoKDM (Knowledge Drive Medicine) platform to answer the specific needs of AGATA, allowing the integration of three different types of DNA data (Illumina NGS, Ion Torrent NGS and Sequenom Massarray), RNA expression profiling data and proteomic data. Based on this integration, OncoKDM will generate a theranostic report, which will quantify the OncoKDM platform’s effectiveness assessment of AGATA.

OncoDNA’s aims to change and advance cancer care by bringing tomorrow’s Cancer Precision Medicine to today’s oncologists’ daily practice. One of the three axes to reach this goal is to provide academic research groups, pathology labs, pharmaceutical and biotech companies with its OncoKDM solution.

Jean-François Laes, CTO of OncoDNA, said: “We are happy that the first OncoKDM collaboration we can announce publicly is with this renowned SOLTI breast cancer group. Our goal when we developed OncoKDM was to propose access to our database and share our expertise. This project gathering molecular data from different technology and geographical origins illustrates the advantage of a centralized, harmonized and expert oncology system to improve cancer patient care.”

About OncoDNA SA

Based in Belgium, OncoDNA is an affiliated company of IPG (Institute of Pathology and Genetics) and is a leading company specialized in the personalized molecular analysis of cancer patients. OncoDNA currently has three services, OncoDEEP&TRACE, OncoDEEP and OncoTRACE. These medical innovations assist medical doctors with treatment choice and/or provide better monitoring of tumor evolution in patients. For more information, please visit www.oncodna.com.

About SOLTI

SOLTI is a non-profit association with more than 20 years of experience in conducting innovative clinical and translational research to address unmet medical needs in breast cancer that answer questions of major scientific interest and relevance in the field of oncology. SOLTI has a network of more than 220 professionals, mostly medical oncologists, distributed in over 60 hospitals in Spain, Portugal, France and Italy. For more information, please visit: www.gruposolti.org.